United States

Choose your country

Select to view the solutions available in your location.

Products and services

Products and services

Learn more about our innovative products and services that help detect cancer earlier and power smarter treatment decisions.
Explore our products

Cancer Risk Starts in the Genes

Exact Sciences is working to eradicate cancer by delivering a portfolio that gives providers the information they need to better serve their patients across the cancer care continuum — starting with familial risk.
Read more
Science

Science

Find out how our scientific rigor, quality standards, and development of future tests make us a leader in cancer testing and treatment guidance.
Explore our science

New England Journal of Medicine Publishes the Science Powering the Next-Generation Cologuard Test

Exact Sciences expects the test to be available in 2025, pending approval.
Read more
About

About

Learn all about Exact Sciences, including our purpose, the people who drive it, our history, and the impact we’ve made.
Learn more about us

Exact Sciences to Employees: ‘Go Volunteer on Work Time’

The company’s commitment to community involvement keeps paying off when employees get back from giving back.
Read more
News and events

News and events

Explore stories, news, and events that highlight our innovation, technology, and people fighting cancer on all fronts.
View news and events

FDA Approves Exact Sciences’ Cologuard Plus™ Test, Setting A New Benchmark in Non-Invasive Colorectal Cancer Screening
Read more
- Press releases
- For media

United States

Choose your country

Select to view the solutions available in your location.

PUBLICATIONS & ABSTRACTS

Rigorous science. Revolutionary solutions.

At Exact Sciences, we are committed to helping patients stay ahead of cancer. Our teams use their scientific expertise to practice innovation driven by robust research and cutting-edge science. We practice thorough, sound research that helps patients face challenging decisions with confidence.

Highlighted publications

Cancer Res

April 2024

Performance of a multi-analyte, multi-cancer early detection (MCED) blood test in a prospectively-collected cohort

View »

Cancer Prevention Research

January 2021

Specificity of the multi-target stool DNA test for colorectal cancer screening in average-risk 45-49 year-olds: a cross-sectional study

View »

Current Medical Research and Opinion

January 2021

Recent trends in colorectal cancer screening methods based on Medicare claims data

View »

PLoS One

December 2020

Estimating the impact of differential adherence on the comparative effectiveness of stool-based colorectal cancer screening using the CRC-AIM microsimulation model

View »

Clinical Gastroenterology and Hepatology

August 2019

Low incidence of aerodigestive cancers in patients with negative results from colonoscopies, regardless of findings from multi-target stool DNA tests.

View »

Journal of Medical Screening

February 2020

Cross-sectional adherence with the multi-target stool DNA test for colorectal cancer screening: real-world data from a large cohort of older adults

View »

Clinical Gastroenterology and Hepatology

September 2020

A Novel Blood-based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma

View »

Click on a cancer type or product below to view corresponding publications and abstracts

View all publications and abstracts »

Colorectal
Cancer

Products
- Oncotype DX Breast DCIS Score test
- Oncotype DX Breast Recurrence Score test
  - Node-negative
  - Node-positive

Pipeline

Esophageal
Cancer

Pipeline

Pancreatic
cancer

Pipeline

Multi-Cancer Early Detection (MCED)

Pipeline

Hereditary Cancer

Pipeline
- Riskguard